Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

RIDGEFIELD, Conn., Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy.

"This FDA Breakthrough Therapy designation provides Boehringer Ingelheim the opportunity to engage in an ongoing dialogue with the FDA  to help expedite the development of volasertib as a potential treatment option for these patients with AML," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, U.S. Regional Medical Director, Boehringer Ingelheim Pharmaceuticals, Inc. "Volasertib is one of many investigational compounds in Boehringer Ingelheim's growing oncology pipeline and is an example of our commitment to exploring treatment approaches with the goal of improving patient outcomes."

The Breakthrough Therapy designation process was established by the FDA in July 2012 and is intended to facilitate and expedite the development and review of drugs for serious or life-threatening conditions if  preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

AML is an aggressive cancer of the bone marrow and blood.2 It accounts for 25 percent of all adult leukemias in the Western world3 and has one of the lowest survival rates of all leukemias.3 In 2013, it is estimated there will be 14,590 new cases of AML diagnosed in the U.S. and 10,370 deaths from the disease.4

AML is primarily a disease of later adulthood; the average age of an AML patient is 65 years.5 A common treatment approach for AML
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  IRIDEX Corporation ... will release its second quarter 2014 financial results after ... In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Control, WASHINGTON, Jan. 10 To help ... risks during times,of health crisis, DuPont (NYSE: ... products, DuPont(TM) Corian(R) solid surface, has been selected,by ... The product,recently was incorporated into a children,s ward ...
... South Korea, Jan. 10 Celltrion, Inc., a ... and CSL Limited, Australia,s leading biopharmaceutical,company, announced today ... supply of CSL 360, an experimental monoclonal antibody ... Phase I clinical trials for CSL,360 are currently ...
Cached Medicine Technology:DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2
(Date:7/25/2014)... Gerontological Society of America (GSA) the ... of aging has chosen Heather M. Young, ... Davis, as the 2014 recipient of the Doris ... honor, presented by GSA,s Health Sciences Section, is ... recognition of outstanding and sustained contribution to gerontological ...
(Date:7/25/2014)... As reported by Wood TV 8 in the ... has seen a nearly 500-person increase in heroin related overdose ... 271 between 1999 and 2002, the toll increased to 728 ... other states, drug users in Michigan have turned to heroin ... compared the price of both substances, noting that an 80-milligram ...
(Date:7/25/2014)... As reported by People Magazine in the article Mike ... Sober (7/15), one of the most popular cast stars ... the public about his personal transformation. Now, two years later ... moving on with his life was a challenge. He was ... 2012 and even spent some time in rehab. He took ...
(Date:7/25/2014)... 25, 2014 The Little Gym of ... on Sunday, July 27 at Discovery Green in downtown ... Copperfield, Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, ... , “We’re thrilled to be attending and performing ... Belcher who owns the Sugarland-Missouri City location. “We believe ...
(Date:7/25/2014)... US (PRWEB) July 25, 2014 ... provider of technology-enabled services for the financial, legal, ... its virtual data room business, Merrill DataSite, has ... Year” presented by GrowthBusiness at the M&A Awards ... recognize the achievements of entrepreneurs, management teams, advisors ...
Breaking Medicine News(10 mins):Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... ... Mom’s site, and National Masturbation Month, Good Vibrations ,Celebrates Spring Fever , ... (PRWEB) -- Good Vibrations, the legendary San ... is proud to announce a fun and sexy new resource for moms at goodvibessexymama.com where ...
... ... ability to digitally sign documents online. , ... (PRWEB) May 13, 2010 -- Secured Signing, a web ... sign documents online with trusted, legally binding signatures. Businesses signing documents online reduce costs, ...
... Non surgical procedure restores the ... ... revolutionary hair replication solution recently at their Edina, Mn, office. They utilize a new process ... restores the permanent look of a full head of hair in one day and develops confidence ...
... The joint ... C.V. to provide a consistent supply of logwood extract used in the production of hematoxylin ... smear tests and hematine is used to dye medical sutures. Abbey Color is the world’s ... ...
... ... tumor surgeon, has been named as one of New York,s "Super Doctors" , ... New York, NY (PRWEB) May 12, 2010 For the ... "New York Super Doctor" in a special section of New York Magazine. As one of ...
... ... 12 of their Premier Literacy Suite of software literacy tools. , ... (PRWEB) May 13, 2010 -- Kenneth Grisham, ... innovation to the field of literacy technology. Our reputation is built on creating robust ...
Cached Medicine News:Health News:Three Ways to Put A Spring In Your Step This Month With Good Vibrations 2Health News:Three Ways to Put A Spring In Your Step This Month With Good Vibrations 3Health News:Signing Documents Online, Now Available for Telecom NZ Business Hub Customers 2Health News:Good Look Ink Announces Revolutionary Hair Replication Solution 2Health News:Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex 2Health News:Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex 3Health News:Manhattan Orthopaedic Oncologist named as "Super Doctor" for 2010 in the New York Times Magazine 2Health News:Manhattan Orthopaedic Oncologist named as "Super Doctor" for 2010 in the New York Times Magazine 3Health News:Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today 2Health News:Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today 3
... In vitro diagnostic reagents for ... (CRP) in human serum as well ... means of particle-enhanced Immunonephelometry using the ... increased levels of a number of ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: